{
    "name": "collagenase clostridium histolyticum",
    "comment": "Rx",
    "other_names": [
        "Xiaflex",
        "Qwo",
        "collagenase clostridium histolyticum-aaes"
    ],
    "classes": [
        "Dermatologics",
        "Other",
        "Urologics",
        "Other",
        "Rheumatologics",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/xiaflex-qwo-collagenase-clostridium-histolyticum-999456",
    "pregnancy": {
        "common": [
            "Data are not available regarding use in pregnant females to evaluate for a drug- associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes "
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "IV administration to pregnant rats during organogenesis at doses up to 0.13 mg/rat (43x human equivalent dose [HED] on a mg/kg basis) revealed no evidence of fetal harm"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding presence in human milk, effects on breastfed children, or on milk production",
            "Following SC injection, systemic concentrations were below the bioanalytical assay limit of quantification "
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Peyronie disease",
                    "description": [
                        "Corporal rupture (penile fracture) was reported as adverse reaction in clinical trials",
                        "Promptly evaluate signs or symptoms reflecting serious penile injury to assess for corporal rupture or severe penile hematoma which may require surgical intervention",
                        "Because of risks of corporal rupture or other serious penile injury, available for the treatment of Peyronie’s disease only through the XIAFLEX REMS Program"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Peyronie plaques that involve the penile urethra"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Do not substitute injectable collagenase products (ie, do not use Xiaflex for cellulite treatment of use Qwo for Dupuytren contracture or Peyronie disease) ",
                "Serious hypersensitivity, including anaphylaxis, reported; if hypersensitivity occurs, discontinue and institute appropriate medical therapy ",
                "Pruritus experienced especially after more injections",
                "Use with caution in patients with coagulation disorders, including in patients who have received anticoagulant medications other than low- dose aspirin within 7 days of the injection",
                "Administration in patients with abnormal coagulation may result in ecchymosis/contusion or an injection site hemorrhage",
                " ",
                "Syncope and Presyncope",
                " "
            ],
            "specific": [
                {
                    "type": "Post-injection back pain",
                    "description": [
                        "Acute post-injection back pain reactions reported in postmarketing period in patients treated for Peyronie’s disease; these events typically have an onset immediately or within minutes of injection",
                        "The acute lower back pain can be mild to severe in intensity and can radiate to the legs, arms and chest; other systemic symptoms, such as chest pain, headache, and dyspnea, reported along with back pain episodes",
                        "None of the events were reported to occur after the patient’s first injection and a few were reported to occur during a second treatment course",
                        "Reported events typically resolved within 15 minutes, but some lasted up to 30 minutes, and one event lasted 1.5 hours; reported events typically did not require intervention, but some required observation and treatment with analgesics"
                    ]
                },
                {
                    "type": "Dupuytren contracture",
                    "description": [
                        "Tendon rupture of other serious injury to the injected extremity reported in clinical trials; avoid injecting into tendons, nerves, blood vessels, or other collagen-containing structure of the hand",
                        "Healthcare providers should be prepared to address hypersensitivity reactions, including anaphylaxis, following injections",
                        "Incidence of skin laceration (22%) was higher when treating 2 concurrent injections compared with up to 3 single injections in the placebo-controlled premarketing trials (9%)",
                        "Postmarketing cases of skin laceration requiring skin graft after finger extension procedures and local skin and soft-tissue necrosis, some requiring skin grafting or, other surgical interventions including finger amputation reported; signs or symptoms that may reflect serious injury to injected finger/hand should be promptly evaluated because surgical intervention may be required"
                    ]
                },
                {
                    "type": "Peyronie Disease",
                    "description": [
                        "Advise patients not to have sex between first and second injections of treatment cycle; patients should wait 2 weeks after second injection of treatment cycle before resuming sexual activity, provided pain and swelling have subsided",
                        "May cause corporal rupture (penile fracture) or other serious injury to penis; avoid injecting into urethra, nerves, blood vessels, corpora cavernosa or other collagen-containing structures of the penis since may result in possible permanent injury (eg, corporal rupture)",
                        "If patient experiences severe pain or swelling of the penis, severe purple bruising and swelling of the penis, difficulty urinating or blood in the urine, sudden loss of ability to maintain an erection, should contact health care provider",
                        "In the postmarketing setting, cases of localized skin and soft tissue necrosis occurring as sequelae of penile hematoma reported; some cases required surgical intervention"
                    ]
                },
                {
                    "type": "Cellulite",
                    "description": [
                        "Cases of syncope and presyncope reported in postmarketing period in patients treated with this medication",
                        "Most, but not all, cases in patients with Peyronie’s disease, occurred in association with post- injection penile pain and hematoma, penile pain with spontaneous erections, and pain during micturition; these potential triggers for the syncopal events suggest a vasovagal mechanism. Make Peyronie’s disease patients aware of the potential for penile pain and painful penile hematoma that could trigger syncope and presyncope after treatment with this drug",
                        "In most cases in patients with Dupuytren’s Contracture, the injection procedure, finger extension procedure, or pain following the procedures were reported as potential triggers for the events, suggesting a vasovagal mechanism; most, but not all cases in patients with Dupuytren’s contracture occurred in the immediate treatment period (injection or finger extension procedure) or within 1-2 days following injection or finger extension procedure",
                        "If presyncope symptoms occur, patients should remain recumbent until symptoms resolve.",
                        "Syncope may be associated with bodily injuries, including concussion, head abrasion, and other accidental injuries"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Injection site bruising is common; patients with coagulation disorders or using anticoagulants or antiplatelets (except aspirin <150 mg/day) were excluded from clinical trials",
                        "Caution if administered to patients with coagulation disorders or coadministered with anticoagulant or antiplatelet agents"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "antithrombin alfa increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "antithrombin III increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "argatroban",
            "description": {
                "common": "argatroban increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "aspirin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "bivalirudin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabigatran",
            "description": {
                "common": "dabigatran increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dalteparin",
            "description": {
                "common": "dalteparin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desirudin",
            "description": {
                "common": "desirudin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "enoxaparin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "fondaparinux increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "heparin",
            "description": {
                "common": "heparin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protein C concentrate",
            "description": {
                "common": "protein C concentrate increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "rivaroxaban increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Peripheral edema",
            "percent": "73"
        },
        {
            "name": "ie",
            "percent": "70"
        },
        {
            "name": "swelling of injected hand",
            "percent": "38"
        },
        {
            "name": "Contusion",
            "percent": "35"
        },
        {
            "name": "Injection site hemorrhage",
            "percent": "35"
        },
        {
            "name": "Injection site reaction",
            "percent": "24"
        },
        {
            "name": "Pain in injected extremity",
            "percent": "24"
        },
        {
            "name": "Tenderness",
            "percent": "15"
        },
        {
            "name": "Injection site swelling",
            "percent": "13"
        },
        {
            "name": "Pruritus",
            "percent": "65.5"
        },
        {
            "name": "Lymphadenopathy",
            "percent": "55"
        },
        {
            "name": "Penile hematoma",
            "percent": "45.4"
        },
        {
            "name": "Penile swelling",
            "percent": "14.5"
        },
        {
            "name": "Penile pain",
            "percent": "84"
        },
        {
            "name": "Penile ecchymoses",
            "percent": "48"
        },
        {
            "name": "Bruising",
            "percent": "33"
        },
        {
            "name": "Pain",
            "percent": "15"
        },
        {
            "name": "Nodule",
            "percent": "9"
        },
        {
            "name": "Pruritus",
            "percent": "8"
        },
        {
            "name": "Skin laceration",
            "percent": "6"
        },
        {
            "name": "Lymph node pain",
            "percent": "6"
        },
        {
            "name": "Erythema",
            "percent": "4.5"
        },
        {
            "name": "Axillary pain",
            "percent": "3.3"
        },
        {
            "name": "Blood blister",
            "percent": "3.1"
        },
        {
            "name": "Penile blister",
            "percent": "2.9"
        },
        {
            "name": "Pruritus genital",
            "percent": "1.8"
        },
        {
            "name": "Painful erection",
            "percent": "1.6"
        },
        {
            "name": "Erectile dysfunction",
            "percent": "1.3"
        },
        {
            "name": "Procedural pain",
            "percent": "1.3"
        },
        {
            "name": "Injection site vesicles",
            "percent": "1.1"
        },
        {
            "name": "Localized edema",
            "percent": "1.1"
        },
        {
            "name": "Dyspareunia",
            "percent": "1.1"
        },
        {
            "name": "Injection site pruritus",
            "percent": "1.1"
        },
        {
            "name": "Nodule",
            "percent": "9"
        },
        {
            "name": "Suprapubic pain",
            "percent": "8"
        },
        {
            "name": "Erythema",
            "percent": "8"
        },
        {
            "name": "Discoloration",
            "percent": "3"
        },
        {
            "name": "Swelling",
            "percent": null
        },
        {
            "name": "Warmth",
            "percent": null
        },
        {
            "name": "Corporal rupture",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "serious hypersensitivity reactions including anaphylaxis",
            "percent": null
        }
    ]
}